Pharmacokinetics and metabolism in early drug discovery

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 373-378

  Smith, Dennis A ^a   Van De Waterbeemd, Han ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOAVAILABILITY; BIOLOGY; CHEMISTRY; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; IN VITRO STUDY; PHARMACOKINETICS; PHARMACOLOGY; REVIEW;

EID: 0033178249     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80056-8     Document Type: Article

References (52)

1. Tarbit MH, Berman J: High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol 1998, 2:411-416.
2. Yalkowski SH, Valvani SC: Solubility and partitioning 1: Solubility of non-electolytes in water. J Pharm Sci 1980, 69:912-922.
3. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997, 23:3-25.
4. Avdeef A: pH-metric solubility. 1. Solubility-pH profiles from bjerrum plots. Gibbs buffer and pKa in the solid state. Pharm Pharmacol Commun 1998, 4:165-178. This paper describes a new method for the measurement of water solubility of drugs.
5. Allen RI, Box KJ, Comer JEA, Peake C, Tam KY: Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs. J Pharm Biomed Anal 1998, 17:699-712.
6. Huuskonen J, Salo M, Taskinen J: Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J Chem Inform Comput Sci 1998, 38:450-456.
7. Huuskonen J, Salo M, Taskinen J: Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997, 86:450-454.
8. Breitkreutz J: Prediction of intestinal drug absorption properties by three-dimensional solubility parameters. Pharm Res 1998, 15:1370-1375.
9. Buchwald P, Bodor N: Octanol-water partition: Searching for predictive models. Curr Med Chem 1998, 5:353-380. This is a good overview of computational methods to estimate log P values. A new, simple method is introduced.
10. Bodor N, Buchwald P: Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B 1997, 101:3404-3412.
11. Buchwald P, Bodor N: Octanol-water partition of nonzwitterionic peptides: Predictive power of a molecular size-based model. Proteins 1998, 30:86-99.
12. Stewart BH, Chung FY, Tait B, John C, Chan OH: Hydrophobicity of HIV protease inhibitors by immobilized artificial membrane chromatography: Application and significance to drug transport Pharm Res 1998, 15:1401-1406.
13. Ducarme A, Neuwels M, GoldStein S, Massingham R: IAM retention and blood brain barrier penetration. Bur J Med Chem 1998, 33:215-223.
14. Reichel A, Begley DJ: Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm Res 1998, 15:1270-1274.
15. AVdeef A, Box KJ, Comer JEA, Hibbert C, Tam KY: pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res 1998, 15:209-215.
16. Raevsky OA, Schaper KJ: Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs. Eur J Med Chem 1998, 33:799-807. This discusses the use of hydrogen bonding descriptors to estimate membrane permeability.
17. Palm K, Luthman K, Ungell A-L, Strandlund G, Beigi F, Lundahl P, Artursson P: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem 1998, 41:5382-5392.
18. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 1999, 88:28-33. This paper describes a good alternative to the more common Caco-2 cell line for screening of absorption potential of putative new drugs.
19. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G: Estimation of permeability by passive diffusion through caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998, 6:313-319. This paper describes the use of various hydrogen bonding and molecular size descriptors to estimate transport through membranes such as Caco-2 cell monolayers.
20. Camenisch G, Folkers G, van de Waterbeemd H: Shapes of membrane permeability-lipophilicity curves: Extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci 1998, 6:321-329.
21. Yazdanian M, Glynn SL, Wright JL, HAwi A: Correlating partitioning and Caco-2 cell permeability of structurally diverse molecular weight compounds. Pharm Res 1998, 15:1490-1494.
22. Sugawara M, Takekuma Y, Yamada H, Kobayashi M, Iseki K, Myazaki K: A general approach for the prediction of the intestinal absorption of drugs: Regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. J Pharm Sci 1998, 87:960-966.
23. Wessel MD, Jurs PC, Tolan JW, Muskal SM: Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inform Comput Sci 1998, 38:726-735. This paper represents a good example of a theoretical approach to estimate human intestinal absorption.
24. Winiwarter S, Bonham NM, Ax F, HAllberg A, Lennernas H, KArlen A: Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998, 41:4939-4949.
25. Van de Waterbeemd H: The fundamental variables of the biopharmaceutics classification system (BCS) - A commentary. Eur J Pharm Sci 1998, 6:1-3.
26. Amidon GL, Lennernäs H, Shah VP, Crison JR: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12:413-420.
27. Norinder U, Sjöberg P, Österberg T: Theoretical calculation and prediction of brain-blood partitioning of organic solutes using molsurf parametrization and PLS statistics. J Pharm Sci 1998, 87:952-959.
28. Fischer H, Gottschlich R, Seelig A: Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J Membr Biol 1998, 165:201-211.
29. Reichel A, Begley DJ: Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm Res 1998, 15:1270-1274.
30. Van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA: Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Targeting 1998, 6:151-165.
31. Spahn-LanggutH H, Baktir G, RAdschwuweit A, OkyAr A, Terhaag B, Ader P, HAnAfy A, Langguth P: P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 1998, 36:16-24. This is an excellent example of studies on the role of P-glycoprotein in limiting oral drug absorption.
32. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M: Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 1998, 87:73-75.
33. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits the oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
34. Prueksaritanont TH, Deluna P, Gorham LM, Ma B, Cohn D, Pang J, Xu X, Leung K, Lin JH: In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos Biol Fate Chem 1998, 26:520-527.
35. Smit JW, Duin E, Steen H, Ousting R, Roggeveld J, Meijer DKF: Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol 1998, 123:361-370.
36. Smit JW, Schinkel AH, Weert B, Meijer DKF: Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol 1998, 124:416-424.
37. Van Asperen J, Van Tellingen O, Beijnen JH: The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998, 37:429-435.
38. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998, 197:252-261.
39. Pascaud C, Garrigos M, Orlowski S: Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 1998, 333:351-358.
40. Makhey VD, Guo A, Norris DA, Hu P, VAN J, Sinko PJ: Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998, 15:1160-1167.
41. Watkins PB: The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Revs 1997, 27:161-170.
42. Wacher VJ, Silverman JA, Zhang Y, Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998, 87:1322-1330.
43. Smith DA, Jones BC, Walker DK: Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Revs 1996, 16:243-266.
44. Van Breemen RB, Nikolic D, Bolton JL: Metabolic screening using online ultrafiltration mass spectrometry. Drug Metab Dispos Biol Fate Chem 1998, 26:85-90.
45. Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT: Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 1995, 25:185-197.
46. Sina JF: Predictive toxicology. Annu Rep Med Chem 1998, 33:283-291.
47. Richard AM: Commercial toxicology prediction systems: A regulatory perspective. Toxicol Lett 1998, 102/103:607-612.
48. Cronin MTD: Computer-aided prediction of drug toxicity in high-throughput screening. Pharm Pharmacol Commun 1998, 4:157-163.
49. Todd MD, Ulrich RG: Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr Opin Drug Discov Devel 1999, 2:58-68.
50. Oldenburg KR: Current and future trends in high throughput screening for drug discovery. Annu Rep Med Chem 1998, 33:301-311.
51. Rodrigues AD: Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res 1997, 14:1504-1510.
52. Kansy M, Senner F, Gubernator K: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998, 41:1007-1010.